TRDA - Entrada Therapeutics, Inc.
IEX Last Trade
17.47
0.045 0.258%
Share volume: 1,596
Last Updated: Fri 27 Dec 2024 08:30:31 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$17.42
0.04
0.26%
Fundamental analysis
32%
Profitability
26%
Dept financing
12%
Liquidity
54%
Performance
38%
Performance
5 Days
1.60%
1 Month
-10.54%
3 Months
7.84%
6 Months
25.19%
1 Year
5.03%
2 Year
17.72%
Key data
Stock price
$17.47
DAY RANGE
$17.22 - $17.53
52 WEEK RANGE
$11.97 - $21.79
52 WEEK CHANGE
$17.56
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
Company detail
CEO: Dipal Doshi
Region: US
Website: entradatx.com
Employees: 110
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: entradatx.com
Employees: 110
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Entrada Therapeutics, Inc. develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for Duchenne muscular dystrophy and myotonic dstrophy type 1.
Recent news